GSK3 inhibition has been shown to be accompanied by a reduction in NFκB activity in osteosarcoma [23], renal cell carcinoma [24], glioma [21], pancreatic [17], [41], [42] and chronic lymphocytic leukaemia [35] cell lines. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.